Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
PITTSBURGH, July 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ:XAGE), a company focused on human longevity and healthy aging ("Longevity", the "Company", "we", "our", or "us"), today announced the execution of a definitive merger agreement (the "Merger") with True Health Inc., a leading player in the fast growing plasma collection industry under the THPlasma brand ("THPlasma"), to combine the companies in an all-stock transaction. Following the closing of the Merger (the "Closing"), the combined company is expected to continue to trade on Nasdaq under the symbol "XAGE." Longevity today also announced the mutual termination of the 20/20 BioLabs transaction purs
Pittsburgh, PA, May 27, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ:XAGE) ("XAGE," the "Company," "we" or "our"), a company dedicated to advancing human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition, today announced the successful sale of 479,621 shares of its common stock at an average price of $4.08 per share through its at-the-market (ATM) equity offering facility. Gross proceeds from the ATM sales totaled approximately $1.96 million, prior to deducting fees and expenses. Assuming no growth beyond the Company's pro forma consolidated FY24 sales and not factoring in the planned 20/20 merger, this financing extends XAGE'
PITTSBURGH, May 21, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ:XAGE) ("XAGE," the "Company," "we," "us," or "our"), a company focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition, today announced that it has received a favorable decision from the Nasdaq Hearings Panel (the "Panel") granting the Company's request to continue its listing on The Nasdaq Stock Market ("Nasdaq") subject to the satisfaction of the Nasdaq initial listing rules for the combined company following the proposed merger with 20/20 BioLabs, Inc. ("20/20") on or before September 2, 2025. This decision follows th
424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)
8-K - Longevity Health Holdings, Inc. (0001842939) (Filer)
25-NSE - Longevity Health Holdings, Inc. (0001842939) (Subject)